Увійти

Готові списки джерел за темами / Biomarker panels / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Biomarker panels.

Статті в журналах з теми "Biomarker panels"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Biomarker panels".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Berben, Lieze, Asier Antoranz, Cindy Kenis, et al. "Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer." Cancers 13, no. 9 (2021): 2185. http://dx.doi.org/10.3390/cancers13092185.

Повний текст джерела

Анотація:

Background: Immune/senescence-related host factors play a pivotal role in numerous biological and pathological process like aging, frailty and cancer. The assessment of these host factors via robust, non-invasive, and easy-to-measure blood biomarkers could improve insights in these processes. Here, we investigated in a series of breast cancer patients in which way single circulating biomarkers or biomarker panels relate to chronological age, frailty status, and tumor-associated inflammatory microenvironment. Methods: An extensive panel of blood immune/senescence markers and the tumor immune in

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Stoker, Aaron, Emily Leary, Chantelle Bozynski, James Stannard, James Cook, and Michael Ewing. "Paper 33: Serum and Urine Biomarkers for Treatment Monitoring after Meniscal Allograft Transplantation in a Preclinical Canine Model." Orthopaedic Journal of Sports Medicine 10, no. 7_suppl5 (2022): 2325967121S0059. http://dx.doi.org/10.1177/2325967121s00597.

Повний текст джерела

Анотація:

Objectives: To analyze serum and urine biomarker concentrations for their capabilities in delineating differences in assessments of pain and functional outcomes after meniscus allograft transplantation (MAT) in a preclinical canine model. The study was designed to test the hypothesis that serum and urine biomarkers could be used for prognostic (1- and 3-month post-surgical time points) and diagnostic (6-month time point) assessments, based on strong associations with clinically relevant pain and function outcomes after MAT. Methods: Twelve adult, purpose-bred research hounds were included and

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Cho, Hyung Joon, Philip Schulz, Lalitha Venkataraman, Richard J. Caselli, and Michael R. Sierks. "Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer’s Disease." International Journal of Molecular Sciences 23, no. 24 (2022): 15670. http://dx.doi.org/10.3390/ijms232415670.

Повний текст джерела

Анотація:

Blood-based biomarkers are needed for the early diagnosis of Alzheimer’s disease (AD). We analyzed longitudinal human plasma samples from AD and control cases to identify biomarkers for the early diagnosis of AD. Plasma samples were grouped based on clinical diagnosis at the time of collection: AD, mild cognitive impairment (MCI), and pre-symptomatic (preMCI). Samples were analyzed by ELISA using a panel of reagents against nine different AD-related amyloid-β (Aβ), tau, or TDP-43 variants. Receiver operating characteristic (ROC) curves of different biomarker panels for different diagnostic sam

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Sprague, Alexander C., Damaris Kuhnell, Wei-Wen Hsu, Trisha Wise-Draper, and Scott Langevin. "Abstract B051: Elastic net discovery of DNA methylation biomarkers for non-invasive diagnosis and recurrence detection in head and neck cancer." Clinical Cancer Research 31, no. 13_Supplement (2025): B051. https://doi.org/10.1158/1557-3265.aimachine-b051.

Повний текст джерела

Анотація:

Abstract Background: Head and neck squamous cell carcinoma (HNSCC) is diagnosed in nearly 60,000 Americans each year. Despite therapeutic advances in recent decades, survival rates have remained largely unchanged. A major contributing factor to poor outcomes is the lack of a non-invasive screening test for HNSCC, as well as the high recurrence rates within two years of curative therapy. In this study, we aimed to leverage elastic net penalized regression to identify and validate DNA methylation biomarkers for HNSCC using non-invasive oral rinse samples. Methods: Oral rinse methylation data fro

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Onoja, Anthony, Johanna von Gerichten, Holly-May Lewis, et al. "Meta-Analysis of COVID-19 Metabolomics Identifies Variations in Robustness of Biomarkers." International Journal of Molecular Sciences 24, no. 18 (2023): 14371. http://dx.doi.org/10.3390/ijms241814371.

Повний текст джерела

Анотація:

The global COVID-19 pandemic resulted in widespread harms but also rapid advances in vaccine development, diagnostic testing, and treatment. As the disease moves to endemic status, the need to identify characteristic biomarkers of the disease for diagnostics or therapeutics has lessened, but lessons can still be learned to inform biomarker research in dealing with future pathogens. In this work, we test five sets of research-derived biomarkers against an independent targeted and quantitative Liquid Chromatography–Mass Spectrometry metabolomics dataset to evaluate how robustly these proposed pa

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Peng, Hong, Sheng Pan, Yuanqing Yan, et al. "Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients." Cancers 12, no. 6 (2020): 1534. http://dx.doi.org/10.3390/cancers12061534.

Повний текст джерела

Анотація:

Background: Diabetes is a risk factor associated with pancreatic ductal adenocarcinoma (PDAC), and new adult-onset diabetes can be an early sign of pancreatic malignancy. Development of blood-based biomarkers to identify diabetic patients who warrant imaging tests for cancer detection may represent a realistic approach to facilitate earlier diagnosis of PDAC in a risk population. Methods: A spectral library-based proteomic platform was applied to interrogate biomarker candidates in plasma samples from clinically well-defined diabetic cohorts with and without PDAC. Random forest algorithm was u

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Jickling, Glen C., and Frank R. Sharp. "Biomarker Panels in Ischemic Stroke." Stroke 46, no. 3 (2015): 915–20. http://dx.doi.org/10.1161/strokeaha.114.005604.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Conway, Susan R., and Hector R. Wong. "Biomarker Panels in Critical Care." Critical Care Clinics 36, no. 1 (2020): 89–104. http://dx.doi.org/10.1016/j.ccc.2019.08.007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Fox, John Leonard, Sugganth Daniel, and Manavi Abrol. "NGS panels' capture of biomarkers associated with targeted therapies in clinical trials." Journal of Clinical Oncology 42, no. 16_suppl (2024): e13508-e13508. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e13508.

Повний текст джерела

Анотація:

e13508 Background: ASCO and NCCN guidelines strongly encourage participation in clinical trials though participation rates remain low. Although up to 60% of trials require biomarker information as a prerequisite to participation, guidelines are silent on biomarker testing to assess eligibility. To help inform policy development, we analyzed commercially available NGS panels to assess the capture rate of the specific gene variants required for targeted therapies in clinical trials. Methods: Publicly available gene variant information on 12 high volume NGS tissue and plasma commercial assays rep

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Higginbotham, Lenora, Lingyan Ping, Eric B. Dammer, et al. "Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease." Science Advances 6, no. 43 (2020): eaaz9360. http://dx.doi.org/10.1126/sciadv.aaz9360.

Повний текст джерела

Анотація:

Alzheimer’s disease (AD) lacks protein biomarkers reflective of its diverse underlying pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used integrative proteomics to identify cerebrospinal fluid (CSF) biomarkers representing a wide spectrum of AD pathophysiology. Multiplex mass spectrometry identified ~3500 and ~12,000 proteins in AD CSF and brain, respectively. Network analysis of the brain proteome resolved 44 biologically diverse modules, 15 of which overlapped with the CSF proteome. CSF AD markers in these overlapping modules were collapsed into five protein pa

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Li, Wenjun, Shaoheng Liang, Hannah Roberts, et al. "Biomarker subpanel customization for different use cases in acute myeloid leukemia research." Journal of Clinical Oncology 41, no. 16_suppl (2023): e19026-e19026. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e19026.

Повний текст джерела

Анотація:

e19026 Background: Treatment guidance and decision making according to modified RECIST guidelines often depends on characterization of these biomarkers in patients with cancer. Although panels with larger breadths of coverage are useful for initial detection of these biomarkers for evaluation of disease burden and prognosis, their cost-effectiveness decreases as treatment and disease progress; smaller subpanels may yield equally valuable information into disease progress and guide treatment in a more cost-effective manner, potentially leading to more datapoints in decision making in comparison

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Sostare, Elena, Thomas N. Lawson, Lucy R. Saunders, et al. "Knowledge-Driven Approaches to Create the MTox700+ Metabolite Panel for Predicting Toxicity." Toxicological Sciences 186, no. 2 (2022): 208–20. http://dx.doi.org/10.1093/toxsci/kfac007.

Повний текст джерела

Анотація:

Abstract Endogenous metabolite levels describe the molecular phenotype that is most downstream from chemical exposure. Consequently, quantitative changes in metabolite levels have the potential to predict mode-of-action and adversity, with regulatory toxicology predicated on the latter. However, toxicity-related metabolic biomarker resources remain highly fragmented and incomplete. Although development of the S1500+ gene biomarker panel has accelerated the application of transcriptomics to toxicology, a similar initiative for metabolic biomarkers is lacking. Our aim was to define a publicly av

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Sahu, Divya, Chen-Ching Lin, and Ajay Goel. "Transcriptomic Profiling Reveals an Enhancer RNA Signature for Recurrence Prediction in Colorectal Cancer." Genes 14, no. 1 (2023): 137. http://dx.doi.org/10.3390/genes14010137.

Повний текст джерела

Анотація:

Background: Colorectal cancer (CRC) is one of the most fatal malignancies worldwide, and this is in part due to high rates of tumor recurrence in these patients. Currently, TNM staging remains the gold standard for predicting prognosis and recurrence in CRC patients; however, this approach is inadequate for identifying high-risk patients with the highest likelihood of disease recurrence. Recent evidence has revealed that enhancer RNAs (eRNAs) represent a higher level of cellular regulation, and their expression is frequently dysregulated in several cancers, including CRC. However, the clinical

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Zou, Ruiyang, Sau Yeen Loke, Veronique Kiak-Mien Tan, et al. "Development of a microRNA Panel for Classification of Abnormal Mammograms for Breast Cancer." Cancers 13, no. 9 (2021): 2130. http://dx.doi.org/10.3390/cancers13092130.

Повний текст джерела

Анотація:

Mammography is extensively used for breast cancer screening but has high false-positive rates. Here, prospectively collected blood samples were used to identify circulating microRNA (miRNA) biomarkers to discriminate between malignant and benign breast lesions among women with abnormal mammograms. The Discovery cohort comprised 72 patients with breast cancer and 197 patients with benign breast lesions, while the Validation cohort had 73 and 196 cancer and benign cases, respectively. Absolute expression levels of 324 miRNAs were determined using RT-qPCR. miRNA biomarker panels were identified b

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Robin, Xavier, Natacha Turck, Alexandre Hainard, Frédérique Lisacek, Jean-Charles Sanchez, and Markus Müller. "Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels intoin vitrodiagnostics?" Expert Review of Proteomics 6, no. 6 (2009): 675–89. http://dx.doi.org/10.1586/epr.09.83.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Leamon, John. "Incorporation of NCCN guideline information in NGS-based cancer testing panel design." Journal of Clinical Oncology 35, no. 15_suppl (2017): e13099-e13099. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e13099.

Повний текст джерела

Анотація:

e13099 Background: NGS has revolutionized medical genomics. However, challenges remain in data analysis and interpretation due to the sheer volume of sequencing data produced. As such, optimized panel design is essential to effectively reduce data analysis burden while ensuring inclusion of critical variants. Ideally a panel should target biomarkers of clinical actionability, such as inclusion an active clinical trial or in the NCCN guideline. As information constantly evolves it is difficult if not impossible for any individual laboratory to capture and reflect real-time view in their panel d

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Lin, Fan, and Haiyan Liu. "Immunohistochemistry in Undifferentiated Neoplasm/Tumor of Uncertain Origin." Archives of Pathology & Laboratory Medicine 138, no. 12 (2014): 1583–610. http://dx.doi.org/10.5858/arpa.2014-0061-ra.

Повний текст джерела

Анотація:

Context Immunohistochemistry has become an indispensable ancillary study in the identification and classification of undifferentiated neoplasms/tumors of uncertain origin. The diagnostic accuracy has significantly improved because of the continuous discoveries of tissue-specific biomarkers and the development of effective immunohistochemical panels. Objectives To identify and classify undifferentiated neoplasms/tumors of uncertain origin by immunohistochemistry. Data Sources Literature review and authors' research data and personal practice experience were used. Conclusions To better guide the

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Pedersen, Camilla Christina, Anastasia Ushakova, Ragnhild Eide Skogseth, et al. "Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders." Neurology - Neuroimmunology Neuroinflammation 10, no. 4 (2023): e200132. http://dx.doi.org/10.1212/nxi.0000000000200132.

Повний текст джерела

Анотація:

Background and ObjectivesNeuroinflammation contributes to Parkinson disease (PD) pathology, and inflammatory biomarkers may aid in PD diagnosis. Proximity extension assay (PEA) technology is a promising method for multiplex analysis of inflammatory markers. Neuroinflammation also plays a role in related neurodegenerative diseases, such as dementia with Lewy bodies (DLB) and Alzheimer disease (AD). The aim of this work was to assess the value of inflammatory biomarkers in newly diagnosed patients with PD and in patients with DLB and AD.MethodsPatients from the Norwegian ParkWest and Dementia St

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Zafari, Sachli, Christina Backes, Eckart Meese, and Andreas Keller. "Circulating Biomarker Panels in Alzheimer's Disease." Gerontology 61, no. 6 (2015): 497–503. http://dx.doi.org/10.1159/000375236.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

McKeigue, Paul. "Sample size requirements for learning to classify with high-dimensional biomarker panels." Statistical Methods in Medical Research 28, no. 3 (2017): 904–10. http://dx.doi.org/10.1177/0962280217738807.

Повний текст джерела

Анотація:

A common problem in biomedical research is to calculate the sample size required to learn a classifier using a (possibly high-dimensional) panel of biomarkers. This paper describes a simple method based on a Gaussian approximation for calculating the predictive performance of the learned classifier given the size of the biomarker panel, the size of the training sample, and the optimal predictive performance (expressed as C-statistic [Formula: see text]) of the biomarker panel that could be obtained if a training sample of unlimited size were available. Under the assumption that the biomarker e

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Emami, Nashmil, and Eleftherios P. Diamandis. "Utility of Kallikrein-Related Peptidases (KLKs) as Cancer Biomarkers." Clinical Chemistry 54, no. 10 (2008): 1600–1607. http://dx.doi.org/10.1373/clinchem.2008.105189.

Повний текст джерела

Анотація:

Abstract Background: The human kallikrein-related peptidase (KLK) family consists of 15 highly conserved serine proteases, which are encoded by the largest uninterrupted cluster of protease genes in the human genome. To date, several members of the family have been reported as potential cancer biomarkers. Although primarily known for their biomarker value in prostate, ovarian, and breast cancers, more recent data suggest analogous roles of KLKs in several other cancers, including gastrointestinal, head and neck, lung, and brain malignancies. Among the proposed KLK cancer biomarkers, prostate-s

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Lin, Fan, Zongming Eric Chen, and Hanlin L. Wang. "Utility of Immunohistochemistry in the Pancreatobiliary Tract." Archives of Pathology & Laboratory Medicine 139, no. 1 (2015): 24–38. http://dx.doi.org/10.5858/arpa.2014-0072-ra.

Повний текст джерела

Анотація:

Context Immunohistochemistry has become a useful ancillary study in the identification and classification of pancreatic neoplasms. The diagnostic accuracy has been significantly improved because of the continuous discoveries of tumor-associated biomarkers and the development of effective immunohistochemical panels. Objectives To identify and classify pancreatic neoplasms by immunohistochemistry. Data Sources Literature review and authors' research data and personal practice experience were used. Conclusions To better guide therapeutic decisions and predict the prognostic outcome, it is crucial

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Km Parul Singh, Km Parul Singh, and Meera kumari Meera kumari. "Tissue inhibitor of metalloproteinase-1 (TIMP-1) – Elevated in liver fibrosis." International Journal of Pharmaceutical Research and Applications 10, no. 3 (2025): 1610–16. https://doi.org/10.35629/4494-100316101616.

Повний текст джерела

Анотація:

Liver diseases, ranging from mild hepatitis to cirrhosis and hepatocellular carcinoma, represent a significant global health burden. Early diagnosis and accurate staging are critical for effective management. Biomarkers have emerged as essential tools in evaluating liver function, injury, inflammation, fibrosis, and regeneration. Among these, Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) has gained considerable attention for its role in liver fibrogenesis. TIMP-1 inhibits matrix metalloproteinases, thereby contributing to extracellular matrix accumulation and fibrosis progression. This revi

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Fox, John Leonard. "Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC)." Journal of Clinical Oncology 41, no. 16_suppl (2023): 3124. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3124.

Повний текст джерела

Анотація:

3124 Background: Next generation sequencing (NGS)-based panels are routinely used in the diagnosis of mNSCLC, guidelines recommending assessing 12 genes for small variants (SV), (EGFR, BRAF, KRAS, MET, ERBB2); fusions (F), (ALK, ROS1, RET, NTRK1, NTRK2, NTRK3); and copy number variants (CNV), (MET) to assess eligibility for targeted drug therapies. Reimbursement is often limited to targeted panels; yet, a comprehensive review of targeted panels’ ability to capture all recommended biomarkers has not been reported. Methods: Targeted panels were classified as ≤50 and 51-100 genes. We searched the

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Attia, Abdelrahman M., Mohammad Saeid Rezaee-Zavareh, Soo Young Hwang, et al. "Novel Biomarkers for Early Detection of Hepatocellular Carcinoma." Diagnostics 14, no. 20 (2024): 2278. http://dx.doi.org/10.3390/diagnostics14202278.

Повний текст джерела

Анотація:

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally. Most patients present with late diagnosis, leading to poor prognosis. This narrative review explores novel biomarkers for early HCC detection. We conducted a comprehensive literature review analyzing protein, circulating nucleic acid, metabolite, and quantitative proteomics-based biomarkers, evaluating the advantages and limitations of each approach. While established markers like alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin, and AFP-L3 remain relevant, promising candidates include circulating tumor DNA,

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Harlid, Sophia, Marc J. Gunter, and Bethany Van Guelpen. "Risk-Predictive and Diagnostic Biomarkers for Colorectal Cancer; a Systematic Review of Studies Using Pre-Diagnostic Blood Samples Collected in Prospective Cohorts and Screening Settings." Cancers 13, no. 17 (2021): 4406. http://dx.doi.org/10.3390/cancers13174406.

Повний текст джерела

Анотація:

This systematic review summarizes the evidence for blood-based colorectal cancer biomarkers from studies conducted in pre-diagnostic, asymptomatic settings. Of 1372 studies initially identified, the final selection included 30 studies from prospective cohorts and 23 studies from general screening settings. Overall, the investigations had high quality but considerable variability in data analysis and presentation of results, and few biomarkers demonstrated a clinically relevant discriminatory ability. One of the most promising biomarkers was the anti-p53 antibody, with consistent findings in on

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Bjerke, Glen, Taylor Patterson, Devin Tauber, et al. "Abstract 4615: Comprehensive genomic profiling using VARIANTPlex™ and FUSIONPlex™ panels along with Archer’s new tumor-only homologous recombination deficiency algorithm." Cancer Research 85, no. 8_Supplement_1 (2025): 4615. https://doi.org/10.1158/1538-7445.am2025-4615.

Повний текст джерела

Анотація:

Comprehensive Genomic Profiling (CGP) for cancer research has arisen out of the need for Next Generation Sequencing (NGS) tests that can be used across tumor types and detect both discreet genomic changes and genome-wide biomarkers. Herein, we detail IDT’s Archer CGP suite of assays, offering cutting-edge precision oncology research solutions designed to provide a thorough and accurate molecular characterization of tumors. This modular set of assays includes VARIANTPlex (DNA) and FUSIONPlex (RNA) profiling with a full range of biomarkers that offer high concordance with established orthogonal

Стилі APA, Harvard, Vancouver, ISO та ін.

28

DaCosta Byfield, Stacey, Bela Bapat, Laura Becker, et al. "Real-world analysis of commercially insured and Medicare Advantage patients with advanced cancer and rates of molecular testing." Journal of Clinical Oncology 41, no. 16_suppl (2023): 6633. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.6633.

Повний текст джерела

Анотація:

6633 Background: Guideline-recommended molecular testing has become essential for biomarker-guided clinical decision making, particularly for patients with advanced (adv) disease. Several biomarkers have indications that are tumor type-agnostic (starting with MSI in 2017, NTRK in 2018, TMB in 2020, and RET and BRAF in 2022). Biomarker testing is covered by insurers, both Medicare (covers comprehensive genomic profiling [CGP] and non-CGP panels) and commercial (at least non-CGP). This study aimed to understand utilization of biomarker testing across tumor types. Methods: This retrospective anal

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Spittle, Daniella A., Alison Mansfield, Anita Pye, Alice M. Turner, and Michael Newnham. "Predicting Lung Function Using Biomarkers in Alpha-1 Antitrypsin Deficiency." Biomedicines 11, no. 7 (2023): 2001. http://dx.doi.org/10.3390/biomedicines11072001.

Повний текст джерела

Анотація:

Lung disease progression in alpha-1 antitrypsin deficiency (AATD) is heterogenous and manifests in different ways. Blood biomarkers are an attractive method of monitoring diseases as they are easy to obtain and repeatable. In non-AATD COPD, blood biomarker panels have predicted disease severity, progression, and mortality. We measured a panel of seven serum biomarkers in 200 AATD patients and compared levels between those with COPD and those without. We assessed whether biomarkers were associated with baseline lung function parameters (FEV1 and TLco) or absolute change in these parameters. In

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Ilie-Mihai, Ruxandra-Maria, Raluca-Ioana Stefan-van Staden, and Jacobus (KOOS) Frederick van Staden. "Review—Progress in Electroanalysis of p53, CEA, and CA19–9." Journal of The Electrochemical Society 169, no. 3 (2022): 037518. http://dx.doi.org/10.1149/1945-7111/ac5cea.

Повний текст джерела

Анотація:

Screening tests for panels of biomarkers such as the panel comprising p53, CEA, and CA19–9 facilitated early diagnosis of cancers and improvement of the quality of life. In this review, diverse electrochemical sensors used for the assay of p53, CEA, and CA 19–9 in biological samples are shown. Different methods of analysis such as differential pulse voltammetry, electrochemical impendance spectroscopy, chronoamperometry, and stochastic method were used for the assay of one biomarker (differential pulse voltammetry, chronoamperometry) or for the assay of a panel of biomarkers comprising p53, CA

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Smith, Bradley J., Licia C. Silva-Costa, and Daniel Martins-de-Souza. "Human disease biomarker panels through systems biology." Biophysical Reviews 13, no. 6 (2021): 1179–90. http://dx.doi.org/10.1007/s12551-021-00849-y.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

de Lemos, James A., and Donald M. Lloyd-Jones. "Multiple Biomarker Panels for Cardiovascular Risk Assessment." New England Journal of Medicine 358, no. 20 (2008): 2172–74. http://dx.doi.org/10.1056/nejme0801721.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Tanase, Cristiana, Radu Albulescu, and Monica Neagu. "Proteomic Approaches for Biomarker Panels in Cancer." Journal of Immunoassay and Immunochemistry 37, no. 1 (2015): 1–15. http://dx.doi.org/10.1080/15321819.2015.1116009.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Wishart, David S., Brendan Bartok, Eponine Oler, et al. "MarkerDB: an online database of molecular biomarkers." Nucleic Acids Research 49, no. D1 (2020): D1259—D1267. http://dx.doi.org/10.1093/nar/gkaa1067.

Повний текст джерела

Анотація:

Abstract MarkerDB is a freely available electronic database that attempts to consolidate information on all known clinical and a selected set of pre-clinical molecular biomarkers into a single resource. The database includes four major types of molecular biomarkers (chemical, protein, DNA [genetic] and karyotypic) and four biomarker categories (diagnostic, predictive, prognostic and exposure). MarkerDB provides information such as: biomarker names and synonyms, associated conditions or pathologies, detailed disease descriptions, detailed biomarker descriptions, biomarker specificity, sensitivi

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Bergman, Nina, and Jonas Bergquist. "Recent developments in proteomic methods and disease biomarkers." Analyst 139, no. 16 (2014): 3836–51. http://dx.doi.org/10.1039/c4an00627e.

Повний текст джерела

Анотація:

Due to the difficulties with poor sample quality, high complexity combined with low concentrations of relevant biomarkers in their respective matrices, the success of proteomics have been rather limited. We have however now finally reached the situation where more and more identified and validated biomarkers/biomarker panels are presented and used in clinical routine.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Long, Jintao, Genhua Pan, Emmanuel Ifeachor, Robert Belshaw, and Xinzhong Li. "Discovery of Novel Biomarkers for Alzheimer’s Disease from Blood." Disease Markers 2016 (2016): 1–9. http://dx.doi.org/10.1155/2016/4250480.

Повний текст джерела

Анотація:

Blood-based biomarkers for Alzheimer’s disease would be very valuable because blood is a more accessible biofluid and is suitable for repeated sampling. However, currently there are no robust and reliable blood-based biomarkers for practical diagnosis. In this study we used a knowledge-based protein feature pool and two novel support vector machine embedded feature selection methods to find panels consisting of two and three biomarkers. We validated these biomarker sets using another serum cohort and an RNA profile cohort from the brain. Our panels included the proteins ECH1, NHLRC2, HOXB7, FN

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Wang, Mingyue, Jermaine Brown, Daniel Lee, et al. "Abstract 7087: Sample-sparing immunoassays for early detection of cancer." Cancer Research 85, no. 8_Supplement_1 (2025): 7087. https://doi.org/10.1158/1538-7445.am2025-7087.

Повний текст джерела

Анотація:

Abstract Research Use Only (RUO) sample-sparing MULTI-ARRAY immunoassays have been developed for several well-established cancer markers. The primary focus of this project is the development of assays to support research of suspicious lung nodules, but many of these selected markers are also relevant to other cancer types. These immunoassays include a serology panel, two biomarker panels, and a single-marker assay. The serology panel includes assays to detect autoantibodies to p53, CTAG-1, and CTAG-2. This panel requires 25 μL of 2, 500-fold diluted serum or plasma. A biomarker panel requiring

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Wen, Zhineng, Ying Huang, Zhougui Ling, et al. "Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis." Disease Markers 2020 (December 10, 2020): 1–10. http://dx.doi.org/10.1155/2020/4716793.

Повний текст джерела

Анотація:

Background. Lung cancer (LC) is top-ranked in cancer incidence and is the leading cause of cancer death globally. Combining serum biomarkers can improve the accuracy of LC diagnosis. The identification of the best potential combination of traditional tumor markers is essential for LC diagnosis. Patients and Methods. Blood samples were collected from 132 LC cases and 118 benign lung disease (BLD) controls. The expression levels of ten serum tumor markers (CYFR21, CEA, NSE, SCC, CA15-3, CA 19-9, CA 125, CA50, CA242, and CA724) were assayed, and that the expression in the levels of tumor markers

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Kane, Laura E., Gregory S. Mellotte, Eimear Mylod, et al. "Abstract PO-008: Diagnostic accuracy of blood-based multi-omic biomarkers for pancreatic adenocarcinoma: A systematic review and meta-analysis." Cancer Research 81, no. 22_Supplement (2021): PO—008—PO—008. http://dx.doi.org/10.1158/1538-7445.panca21-po-008.

Повний текст джерела

Анотація:

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreatic cancer, being responsible for ~90% of all pancreatic cancers and having a 5-year survival rate of ~8.5%. The current clinical gold-standard for diagnosis of PDAC is the blood-based biomarker CA19-9. However, many studies have highlighted the limitations of CA19-9, specifically its relatively low sensitivity and specificity, and its inaccuracy in patients with certain underlying conditions. As such, there is an unmet need for robust diagnostic biomarkers for PDAC. Here, the diagnostic accuracy of

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Silberberg, Gilad, Stefano Cairo, Mara Gilardi, Brandon Walling, Marianna Zipeto, and Michael Ritchie. "Abstract 3717: A digital patient & simulated clinical trial of cytarabine treatment." Cancer Research 85, no. 8_Supplement_1 (2025): 3717. https://doi.org/10.1158/1538-7445.am2025-3717.

Повний текст джерела

Анотація:

Abstract Historically, computational models have primarily relied on single-omic datasets, particularly transcriptomic data, to predict cancer sensitivity to drugs. These models often identified single gene alterations as biomarkers of drug response. While informative, the predictive potential of these biomarker panels remains limited. Moreover, these same panels have failed to predict potential toxicities associated with anti-cancer drugs. This underscores the urgent need to construct more robust biomarker panels capable of not only predicting patient response but also anticipating potential

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Lie, Wen-Rong, and Jehangir Mistry. "Proteomic profiling of activated immune cells using quantitative multiplex bead-based assays to identify secretome and cell signaling protein signatures (TECH1P.869)." Journal of Immunology 192, no. 1_Supplement (2014): 69.37. http://dx.doi.org/10.4049/jimmunol.192.supp.69.37.

Повний текст джерела

Анотація:

Abstract Multiplex bead-based assays using the Luminex® xMAP® technology allows the simultaneous quantitation of soluble mediators involved in adaptive immune responses. Here we report on the quantitative profiling of the immune secretome and cell signaling target proteins to uncover the characteristics of a CD40L/IFN-γ-activated mature dendritic cell (DC)-based vaccine and the characteristics of T-cell responses generated upon vaccination. Over 200 secreted proteins were evaluated using the Human MILLIPLEX® MAP magnetic bead panels (Cytokine/Chemokine Panels 1-3, High Sensitivity T Cell Panel

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Glineur, S., V. Gryshkova, J. P. Valentin, and A. Nogueira da Costa. "Taking safety biomarkers ‘out of the box’: biomarker panels and drug induced injuries." Toxicology Letters 295 (October 2018): S43. http://dx.doi.org/10.1016/j.toxlet.2018.06.1173.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Schmitt, Anthony, Kristin Sikkink, Kristyn Galbraith, Misha Movahed-Ezazi, George Jour, and Matija Snuderl. "Abstract LB291: Uncovering gene fusions with 3D genomics: from clinical validation to actionable insights for undiagnosable solid tumors." Cancer Research 83, no. 8_Supplement (2023): LB291. http://dx.doi.org/10.1158/1538-7445.am2023-lb291.

Повний текст джерела

Анотація:

Abstract Identifying gene fusions in tumor biopsies is critical for understanding disease etiology; however, clinical NGS panels often fail to yield clear genetic drivers. A key challenge is that RNA-seq does not perform well in FFPE tissue blocks due to RNA degradation and/or RNA panel design, and cannot detect breakpoints outside of the gene body, which are established clinical biomarkers with mechanistic significance and clinical utility in solid hematological cancers. We developed a novel DNA-based partner-agnostic approach for identifying fusions from FFPE tumors using 3D genomics based o

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Jadav, Radhika Kiritsinh, Reza Mortazavi, and Kwang Choon Yee. "Blood Biomarkers for Triaging Patients for Suspected Stroke: Every Minute Counts." Journal of Clinical Medicine 11, no. 14 (2022): 4243. http://dx.doi.org/10.3390/jcm11144243.

Повний текст джерела

Анотація:

Early stroke diagnosis remains a big challenge in healthcare partly due to the lack of reliable diagnostic blood biomarkers, which in turn leads to increased rates of mortality and disability. Current screening methods are optimised to identify patients with a high risk of cardio-vascular disease, especially among the elderly. However, in young adults and children, these methods suffer low sensitivity and specificity and contribute to further delays in their triage and diagnosis. Accordingly, there is an urgent need to develop reliable blood biomarkers for triaging patients suspected of stroke

Стилі APA, Harvard, Vancouver, ISO та ін.

45

He, Weisi, Jingyu Cui, Xue-Yan Wang, Ryan H. P. Siu, and Julian A. Tanner. "Early-Stage Pancreatic Cancer Diagnosis: Serum Biomarkers and the Potential for Aptamer-Based Biosensors." Molecules 30, no. 9 (2025): 2012. https://doi.org/10.3390/molecules30092012.

Повний текст джерела

Анотація:

Pancreatic cancer has a high mortality rate, and both the incidence and mortality are continuing to increase in many countries globally. The poor prognosis of pancreatic cancer is in part due to the challenges in early diagnosis. Improving early-stage pancreatic cancer diagnosis would improve survival outcomes. Aptamer-based biosensors provide an alternative technological approach for the analysis of serum biomarkers with several potential advantages. This review summarizes the major pancreatic cancer serum biomarkers, as well as discusses recent progress in biomarker exploration and aptasenso

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Neagu, Monica, Carolina Constantin, Cristiana Tanase, and Daniel Boda. "Patented Biomarker Panels in Early Detection of Cancer." Recent Patents on Biomarkerse 1, no. 1 (2011): 10–24. http://dx.doi.org/10.2174/2210309011101010010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Neagu, Monica, Carolina Constantin, Cristiana Tanase, and Daniel Boda. "Patented Biomarker Panels in Early Detection of Cancer." Recent Patents on Biomarkers 1, no. 1 (2011): 10–24. http://dx.doi.org/10.2174/2210310411101010010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Fortino, V., G. Scala, and D. Greco. "Feature set optimization in biomarker discovery from genome-scale data." Bioinformatics 36, no. 11 (2020): 3393–400. http://dx.doi.org/10.1093/bioinformatics/btaa144.

Повний текст джерела

Анотація:

Abstract Motivation Omics technologies have the potential to facilitate the discovery of new biomarkers. However, only few omics-derived biomarkers have been successfully translated into clinical applications to date. Feature selection is a crucial step in this process that identifies small sets of features with high predictive power. Models consisting of a limited number of features are not only more robust in analytical terms, but also ensure cost effectiveness and clinical translatability of new biomarker panels. Here we introduce GARBO, a novel multi-island adaptive genetic algorithm to si

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Kim, Hongbeom, Kyung Nam Kang, Yong Sung Shin, et al. "Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma." Cancers 12, no. 6 (2020): 1443. http://dx.doi.org/10.3390/cancers12061443.

Повний текст джерела

Анотація:

A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance in the diagnosis of pancreatic ductal adenocarcinoma (PDAC). We used blood samples from 180 PDAC patients and 573 healthy controls. Candidate markers consisted of 11 markers that are commonly expressed in various cancers and which have previously demonstrated increased expression in pancreatic canc

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Mazzone, Peter J., Xiao-Feng Wang, Xiaozhen Han, et al. "Evaluation of a Serum Lung Cancer Biomarker Panel." Biomarker Insights 13 (January 1, 2018): 117727191775160. http://dx.doi.org/10.1177/1177271917751608.

Повний текст джерела

Анотація:

Background: A panel of 3 serum proteins and 1 autoantibody has been developed to assist with the detection of lung cancer. We aimed to validate the accuracy of the biomarker panel in an independent test set and explore the impact of adding a fourth serum protein to the panel, as well as the impact of combining molecular and clinical variables. Methods: The training set of serum samples was purchased from commercially available biorepositories. The testing set was from a biorepository at the Cleveland Clinic. All lung cancer and control subjects were >50 years old and had smoked a minimum of

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!